Loading company…
Neowise develops TCR-T cell therapies for solid tumors.
Founded in 2020 and based in Suzhou, China, Neowise Biotechnology develops autologous TCR-T therapies targeting tumor-associated antigens in solid tumors. Its platform supports TCR discovery, validation, and development across multiple clinical-stage programs. In October 2025, the company raised over 200 million in Series B funding led by Apricot Capital, with participation from Delian Capital, Suzhou Angel Investment Guidance Fund, Oriza Holdings, Shenzhen Green Eco-Manufacture Hi-Tech Co., Ltd., and Shanghai Tonggao Investment Management Co., LTD.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in